Kyowa Kirin Co., Ltd.

Riken Corporation

Kyowa Hakko Kirin Co., Limited

Masakazu Homma

Shigeyuki Yokoyama

Yasuhisa Shiraishi

Kensaku Sakamoto

Akiko Matsumoto

Tatsuo Yanagisawa

Akifumi Kato

Kaname Kimura

Yoshimi Yamaguchi

Kazumasa Ohtake

Yasuhiro Suzuki

Kenji Uchida

Keiji Uehara

Yuichi Fukuda

Junichiro Yamamoto

Seiji Aratake

Toshimi Kanai

Tatsuya Ishimori

Toshimasa Harumoto

Fumikazu Shinohara

Hiroto Iwai

Tatsuto Kiuchi

Kenji Hagiwara

The present invention relates to a monoclonal antibody or antibody fragment thereof as a human IgG antibody including at least one lysine derivative in a constant region of the human IgG antibody; a modified antibody or antibody fragment thereof, wherein the lysine derivative is modified; a nucleic acid including a nucleotide sequence encoding the antibody or antibody fragment thereof; a vector including the nucleic acid; a transformed cell obtained by introducing the vector into a host cell; a method for producing the antibody or antibody fragment thereof; and a composition containing the antibody or antibody fragment thereof.

Antibody with non-natural amino acid introduced therein

The present invention relates to a nucleic acid conjugate represented by the following formula 1: wherein X is an oligonucleotide, L1 and L2 are each independently sugar ligand, and S1, S2 and S3 are each independently a linker.

Nucleic acid conjugate

The present invention provides a heterocyclic compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof, in which X, R, Y, R, R, and Rare as defined herein. The compound of formula (I) inhibits a C-C chemokine receptor type 10 (CCR10) receptor and is useful as a prophylactic and/or therapeutic agent for skin diseases.

Substituted pyridines and pyridazines as CCR10 receptor inhibitors

Growing community of inventors

Tokyo, Japan

Masakazu Homma